Bristol, United Kingdom
EnsiliTech, founded in 2022, is an innovative company based in the United Kingdom, revolutionizing the pharmaceutical landscape with its disruptive Ensilication technology. Their compelling slogan, "Creating biologicals without refrigeration," succinctly captures their unique value proposition.
This breakthrough technology uses silica to form protective nanoshells around essential biomolecules such as vaccines, antibodies, and enzymes. By eliminating the need for cold chain infrastructure, EnsiliTech not only facilitates global distribution and accessibility of these products but also significantly reduces waste and emissions, aligning with sustainable practices in the pharmaceutical supply chain.
The company's recent financial momentum includes a substantial £4.50M Seed investment received on 01 August 2025, backed by a strong syndicate of investors including Chicago ArchAngels, Calculus Capital, and Capital Partners, among others. This investment emphasizes robust confidence in EnsiliTech's potential for industry-wide impact.
